FDA Approves First Generic of Roche’s Cancer Drug Xeloda
October 1, 2013
The FDA Sept. 16 approved Teva’s generic version of Roche’s cancer drug Xeloda. It is the first generic copy of Xeloda (capecitabine), an oral chemotherapy pill, to gain the FDA’s approval. The drug is indicated to treat cancer of the colon or rectum that has spread to other parts of the body and metastatic breast cancer. Teva will market generic capecitabine in 150 mg and 500 mg strengths.